Siemens Healthineers Transforms Care Delivery with Innovative New Tests for Diagnosing Heart Attacks Faster

Malvern, PA|07/26/2018

• The Siemens Healthineers High-Sensitivity Troponin I assays can detect lower levels of troponin compared to conventional assays.
• Troponin indicates damage to the heart muscle, and greater precision measures slight, yet critical, changes so physicians can properly triage patients sooner.
• The TnIH assays that enable fast results and earlier diagnosis for heart attack patients are now available in the U.S.

Siemens Healthineers announced today it is helping to shorten the time doctors can diagnose a life-threatening heart attack with the introduction of two assays that offer unparalleled precision. U.S. Food and Drug Administration cleared High-Sensitivity Troponin I assays (TnIH)1 for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers from Siemens Healthineers to aid in the early diagnosis of myocardial infarctions—commonly known as heart attacks. When a patient experiencing chest pain enters the emergency department, a physician orders a blood test to determine whether troponin is present. As blood flow to the heart is blocked, the heart muscle begins to die in as few as 30 to 60 minutes and releases troponin into the bloodstream.

The high-sensitivity performance of the two new Siemens Healthineers TnIH assays offers the ability to detect lower levels of troponin at significantly improved precision at the 99th percentile, and detect smaller changes in a patient’s troponin level as repeat testing occurs. This design affords clinicians greater confidence in the results with precision that provides the ability to measure slight, yet critical, changes to begin treatment.2,3 As science progresses, guidelines for determining high-sensitivity also evolves. These TnIH assays meet the latest industry guidelines.

Chest pain is the cause of more than eight million visits annually nationwide to emergency departments, but only 5.5 percent of those visits lead to serious diagnoses such as heart attacks.4 Armed with data to properly triage patients sooner or to exclude myocardial infarctions, the Siemens Healthineers TnIH assays can help support testing initiatives tied to improving patient experience.

“Our emergency department is overcrowded with patients. If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system,” said Dr. Alan Wu, Chief of Clinical Chemistry and Toxicology at Zuckerberg San Francisco General Hospital and Trauma Center.

Learn more about High-Sensitivity Troponin I from Siemens Healthineers in booth #2812 during the 70th AACC Annual Scientific Meeting & Clinical Lab Expo taking place from July 31 to August 2 in Chicago, Ill.

1 Product availability may vary from country to country and is subject to varying regulatory requirements.
2 Eggers K, Jernberg T, Ljung L, Lindahl B. High-Sensitivity Cardiac Troponin-Based Strategies for
the Assessment of Chest Pain Patients—A Review of Validation and Clinical Implementation Studies. Clin Chem. 2018;64(7). DOI: 10.1373/clinchem.2018.287342
3 Collinson P. High-sensitivity troponin measurements: challenges and opportunities for the laboratory and the clinician. Annals of Clinical Biochemistry. 2016;53(2) 191–195. DOI: 10.1177/0004563215619946
4 Hsia RY, Hale Z, Tabas JA. A National Study of the Prevalence of Life-Threatening Diagnoses in Patients With Chest Pain. JAMA Intern Med. 2016;176(7):1029–1032. DOI:10.1001/jamainternmed.2016.2498

Contact for journalists
Kimberly Nissen, Siemens Healthineers
Phone: +1 610 448-6355; Email:

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at